Here, we report for the first time the clinical efficacy of first-line furmonertinib in patients with advanced NSCLC harboring uncommon EGFR ex20ins mutations (p.S768_D770dupSVD and p.N771_P772insVal) in the real-world. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.